Published in
Oxford University Press (OUP), Neuro-Oncology, suppl_6(19), p. vi182-vi182
DOI: 10.1093/neuonc/nox168.740
Links
Tools
PATH-51. OUTCOME IN 1p/19q NON-CO-DELETED GLIOMA TREATED AT FIRST RECURRENCE WITH TEMOZOLOMIDE W/Wo BEVACIZUMAB IS DEPENDENT ON IDH, MGMT AND CIMP STATUS, BUT NOT ON GRADE AT FIRST DIAGNOSIS. A REPORT FROM THE RANDOMIZED PHASE II EORTC TAVAREC TRIAL
Journal article published in 2017 by
Pim French,
Iris de Heer,
Kaspar Draaisma,
Johan Kros,
W. Taal 
,
Jacolien Bromberg,
Paul Clement,
Ahmed Idbaih,
Filip de Vos ,
Antje Wick,
Paul Mulholland,
Martin Taphoorn,
Joanne Lewis,
Tina Verschuere,
Vassilis Golfinopoulos
and other authors.
,
Jacolien Bromberg,
Paul Clement,
Ahmed Idbaih,
Filip de Vos ,
Antje Wick,
Paul Mulholland,
Martin Taphoorn,
Joanne Lewis,
Tina Verschuere,
Vassilis Golfinopoulos
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 